🟢 Telix Pharmaceuticals is trading 4.28% up today after strong first-half 2026 results

Telix Pharmaceuticals is trading A$17.56, 4.28% up after reporting strong first-half 2026 results on August 20, 2026.

• Revenue rose 22% year-over-year to US$477 million; adjusted EBITDA jumped 146% to US$52 million.
• Management reaffirmed FY2026 revenue guidance of US$950–970 million and expects revenue plus other income to exceed US$1 billion.
• Pipeline progress and a new ATM facility may temper enthusiasm through potential dilution.